A study from Weill Cornell Medical College, New York suggests patients with metabolic syndrome may be at increased risk for clear cell renal cell carcinoma.
Study evaluates patient experiences with biopsy-based genomic testing during active surveillance
Michael S. Leapman, MD, MHS, highlights a study of patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry
Researchers identified 9 novel susceptibility loci for prostate cancer, 7 of which were substantially more prevalent in patients of African ancestry.
Speaking of Urology: ASCO GU 2023 Highlights
Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
Study shows potential of PSMA-targeted therapy in non-metastatic CRPC
The PSMA-targeted monoclonal antibody J591 is effective in non-metastatic CRPC when it is radiolabeled with either 177Lu or 111In.
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy
"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
2 Clarke Drive Cranbury, NJ 08512